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Bruton tyrosine kinase (BTK) is a non-receptor protein kinase that belongs to the TEC family 
kinases. It plays an important role in the B-cell receptor signaling pathway (BCR) and its 
pharmacological inhibition has been demonstrated as an effective strategy for the treatment of 
B-cell malignancies. Ibrutinib, acalabrutinib and zanubrutinib are small molecules and 
irreversible BTK binders that have been approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for the treatment of several B-cell 
malignancies. Irreversible inhibitors block BTK catalytic activity by covalently binding to the 
cysteine (C) 481 located in the kinase domain. Mutations at this residue abrogate the possibility 
of forming a covalent bond, thereby decreasing the efficacy of the inhibitor. The most common 
mutation found in treated patients is the cysteine-481 to serine substitution (C481S). However, 
other less frequent substitutions have also been identified, such as, T474I and T474S 
substitutions in the BTK gatekeeper residue or PLCg2 gain-of-function substitutions e.g. 
S707Y and R665W. 
In paper I we studied a novel C481S knock-in mouse model. Our analysis of these mice 
reveled no phenotype alterations, as compared to wild-type mice, and demonstrated that C481S 
substitution has no detectable effect on BTK´s function or on the development of hematopoietic 
cells. We demonstrated that isolated B-lymphocytes carrying C481S were resistant to 
irreversible but sensitive to reversible BTK inhibitors (BTKis). This was achieved by analyzing 
BTK catalytic activity, cell-viability and expression of cell activation markers. Additionally, 
we confirmed that irreversible BTKis impaired T-lymphocyte activation in a BTK independent 
manner. This demonstrates the potential of this mouse model to be used in the study of BTK-
independent, both therapeutic and adverse, effects caused by irreversible BTKis. 
Resistance to BTKis has become one of the most critical concerns in long term ibrutinib treated 
patients. The cause of the resistance to irreversible BTKis is less frequently associated to the 
gatekeeper residue, in contrast what is observed for other kinase inhibitors such as the fusion-
protein BCR-ABL inhibitor imatininb or the EGFR inhibitor gefitinib. In paper II we aimed 
to understand the role of gatekeeper and combined gatekeeper/C481 BTK variants in the 
resistance to reversible and irreversible BTKis. We evaluated protein expression, catalytic 
activity and susceptibility to BTKis of 16 BTK single and double variants. We found that 
double T474I/C481S, T474M/C481S and T474M/C481T variants were insensitive to ³16 fold 
irreversible inhibitor pharmacological serum concentration. On the other hand, reversible 
BTKis showed a variable inhibition pattern. RN486 seemed to have highest therapeutic 
potential for patients that develop resistance to combined gatekeeper/C481 BTK variants.   
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LIST OF ABBREVIATIONS 
 
AF Atrial fibrillation 
AID Activation-induced cytidine deaminase 
ALK Anaplastic lymphoma kinase 
ARA Autosomal recessive agammaglobulinemia 
ATP Adenosine triphosphate 
BCR B-cell receptor 
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BLK B-lymphoid kinase 
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ERBB2/HER2 Human epidermal growth factor receptor 2 
ERBB4/HER4 Human epidermal growth factor receptor 4 
FBS Fetal bovine serum 
FDA Food and Drug Administration  
FMO Fluorescence minus one 




ITAM Immunoreceptor tyrosine-based activation motif 
ITK Inducible T-cell kinase 
JAK3 Janus kinase 3 
KO Knock-out 
LPS Lipopolysaccharide 
MCL Mantle cell lymphoma 
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MZ Marginal zone 
MZL Marginal zone lymphoma 
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PI3K Phosphatidylinositol-3-kinase 
PKC Protein kinase C 
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PMDA Pharmaceuticals and Medical Devices Agency 
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RLK/TXK Resting lymphocyte kinase/ T and X cell expressed kinase 
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SYK Spleen tyrosine kinase 
TEC Tyrosine kinase expressed in hepatocellular carcinoma 
TFKs TEC family kinases 
TH Tec homology domain 
TNFa Tumor necrosis factor a 
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1.1 B-lymphocyte development  
After birth and continuously throughout the whole life, B-lymphocytes develop from 
hematopoietic stem cells (HSCs) in the bone marrow (BM). The first stage of the specific B-
cell development starts with the pro-B cell, which expresses the B-cell lineage-specific cluster 
of differentiation (CD) 19. It is at this stage of the development that the immunoglobulin (Ig) 
heavy chain initiates the diversity (D) and joining (J) rearrangement (Boekel et al., 1995). The 
transition from pro-B cell to the next stage pre-B cell, depends on a productive variable (V) DJ 
rearrangement and the expression of the µ heavy chain associated with the surrogate light chain 
(Übelhart et al., 2015). Pre-B cell loses CD117 (c-kit) marker, gains CD25 expression and 
undergoes VJ light chain rearrangement. Efficient heavy-light chains pairing and the 
consequent expression of the formed and functional B-cell receptor (BCR) are required for the 
transition from pre-B to immature B-cell stage. Immature B-cells that will exit from the BM 
migrate to the second lymphoid tissues and upon alternative splicing acquire the IgD surface 
marker, which in co-expression with IgM characterizes transitional and mature B-cells 
populations (Osmond, 1991; Ochs et al., 2013; Pieper et al., 2013).     
Mature B-cells could be classified into B-1 and B-2 subsets. The self-renewing B-1 cells secrete 
natural antibodies and contribute to T-cell independent responses. The mature B-2 cell 
population is constituted by follicular B-cells and the spleen-enriched marginal zone (MZ) 
subset (Ochs et al., 2013). The follicular B-cells express CD21+/CD23+/IgMlo/IgDhi markers, 
respond to T-cell dependent antigens and could be differentiated into plasma and memory B-
cells. Whereas, CD21+/CD23-/IgMhi/IgDlo MZ B-cells are the main producers of IgM 
antibodies and preferentially respond to T-cell independent antigens (Appelgren et al., 2018). 
In response to antigen binding, upregulation of activation-induced cytidine deaminase (AID) 
is observed. AID mediates somatic hypermutation of the V region in both heavy and light 
chains, and immunoglobulin class switch recombination that replaces the µ constant region 
generating IgA, IgG or IgE antibodies. Ultimately, mature cells expressing different types of 
Ig are positively selected and produce long lived memory B-cells and plasma cells (Abbas et 
al., 1993; MacLennan, 1994; Ochs et al., 2013; Pieper et al., 2013).           
 
1.2 Tyrosine kinases 
TEC family kinases (TFKs) are non-receptor Protein Tyrosine Kinases (PTKs) that 
phosphorylate selected tyrosine residues on a substrate protein. Five members in the TFKs have 
been described, including Bruton Tyrosine Kinase (BTK), tyrosine kinase expressed in 
hepatocellular carcinoma (TEC), inducible T-cell kinase (ITK), resting lymphocyte kinase/T 
and X cell expressed Kinase (RLK/TXK) and bone marrow-expressed kinase (BMX) (Smith 
et al., 2001). 
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BTK and TEC play an important role in the B-cell development. BTK is a key component in 
the BCR signaling pathway and its expression has been reported in all hematopoietic cells with 
the exception of T- and plasma cells (Smith et al., 1994; Schmidt et al., 2004). TEC is expressed 
in platelets, erythrocytes, macrophages, neutrophils, endothelial, B- and T-cells, as reviewed 
by (Berglöf et al., 2015).  
ITK is expressed in mast, NK- and T-cells (Schmidt et al., 2004). Mutations in the ITK gene in 
humans cause severe Epstein-Barr virus dysregulation (Ghosh et al., 2018) and ITK knock-out 
(KO) mice have decreased number of mature thymocytes and lowered ratio of CD4+/CD8+ 
cells (Liao and Littman, 1995). A more severe phenotype is observed in ITK/TXK mice, 
suggesting that TXK is also involved in T- and NKT-cell development (Broussard et al., 2006; 
Felices and Berg, 2008).  
BMX is weakly expressed in macrophages and neutrophils but mainly in endothelial cells. It is 
involved in the response to ischemia, as well as survival and tumorigenicity of glioblastoma 
cancer stem cells (Cenni et al., 2012).  
 
1.3 Bruton Tyrosine Kinase and B-cell development 
The BTK gene is located on the X chromosome, region Xq22.1 (Vetrie et al., 1993). It encodes 
a 2.7 kb mRNA that is translated into a cytoplasmic PTK constituted by 659 amino acids 
(Tsukada et al., 1993; Vetrie et al., 1993; Smith et al., 1994). The structure of the BTK-protein 
consists of five different domains. From the C-terminal, BTK carries three SRC homology 
domains (SH), a SH1 or kinase domain, followed by SH2 and SH3 that interact with 
phosphorylated tyrosine residues and proline-rich stretches, respectively. Pleckstrin homology 
(PH) and Tec homology (TH) domains are located at the N-terminal and contain membrane-
targeting function, a designated Btk motif and proline-rich stretch (Smith et al., 1994; Salim et 
al., 1996; Vihinen et al., 1997). 
Mutations in the BTK gene in humans block the B-cell development and cause X-linked 
agammaglobulinemia (XLA). XLA is the most common form of inherited 
agammaglobulinemia in man and was reported for the first time in 1952 by Ogden C. Bruton 
(Bruton, 1952; Hendriks et al., 2011). Patients with either XLA or autosomal recessive 
agammaglobulinemia (ARA) present increased susceptibility to bacterial infections in the 
respiratory tract and also to enteroviral infections that could progress and cause death 
(Lederman and Winkelstein, 1985; Ochs et al., 2013). XLA and ARA are differentiated from 
other Ig deficiencies by the arrest in the B-cell development, during the pro-B to pre-B cell 
stage (Tsukada et al., 1993; Vetrie et al., 1993; Ochs and Smith, 1996; Noordzij et al., 2002).  
XLA patients are characterized by increased number of pro-B cells, decreased immature B-
cells and almost total lack of mature B-cells, plasma cells and immunoglobulin production 
(Figure 1). Therefore, XLA patients are highly susceptible to extracellular bacterial and 
enteroviral infections (Ochs and Smith, 1996; Noordzij et al., 2002; Winkelstein et al., 2006).  
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On the other hand, a missense mutation in the mouse Btk gene causes X-linked 
immunodeficiency (Xid). This is a less severe defect, characterized by partial block in the pre-
B cell stage of the B-cell development (Figure 1) (Scher, 1982; Khan et al., 1995). The Xid 
phenotype resembles the one found in the BTK KO mouse model (Khan et al., 1995). Even 
though Xid mice have less severe disease, similar phenotype to human XLA could be seen in 
mice with double KO for BTK and TEC (BTK/TEC dKO). This difference in phenotype may 
be explained by the ability of TEC to compensate BTK function in mice (Figure 1) (Ellmeier 
et al., 2000). However, results from TEC KO animals demonstrated that TEC is not essential 
for the B-cell development, since TEC-deficient mice did not show any characteristic 
phenotype (de Bruijn et al., 2017).  
 
Figure 1. Scheme representing the B-cell differentiation block in XLA, Xid and BTK/TEC dKO mice.  
 
Xid phenotype is characterized by small increase of B220+/CD43+ B-cells, lack of CD5+ B1a 
cells in peritoneal cavity (Scher, 1982; Khan et al., 1995; Ellmeier et al., 2000)  and reduction 
of two- to three fold of B-cell populations in spleen, with mainly IgMlo/IgDhi B-cells decreased 
by half (Khan et al., 1995; Ellmeier et al., 2000). In contrast to the reduction of all 
immunoglobulin classes observed in XLA patients, only reduced IgM, IgG2 and very low IgG3 
levels are observed in Xid mice (Scher, 1982; Khan et al., 1995; Ellmeier et al., 2000).  
The severe phenotypic alteration observed in the BTK/TEC dKO is caused by a stronger block 
in the B-cell development (Figure 1), evidenced by the BM accumulation of CD43+ pro-B cells 
and the dramatically reduced frequency of peripheral B220+ B-cells, particularly mature 
IgMlo/IgDhi B-cells in spleen (wild-type 49.8%; BTK/TEC dKO 7.7%) and lymph nodes (wild-
type 63.1%; BTK/TEC dKO 3.9%) (Ellmeier et al., 2000). Similar to Xid mice, decreased 
serum IgM, IgG2a and IgG3 levels are observed in BTK/TEC dKO mice. In contrast to the 
minor structural alterations observed in spleen from Xid mice, BTK/TEC dKO has fewer 
clearly defined small follicular structures, unclear or discontinued MOMA-1+ MZ macrophage 
layer and reduced frequency of germinal centers (Khan et al., 1995; Ellmeier et al., 2000). 
 
Stem cell                      Pro-B cell                           Pre-B cell                  B lymphocyte                 Plasma cell   
X-linked agammaglobulinemia X-linked immunodeficiency Total blockPartial block BTK/TEC double knockout 
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1.4 BTK in the B-cell receptor signaling pathway 
Each B-cell expresses a unique BCR, which is composed of two identical immunoglobulin 
heavy and light chains coupled by a disulfide-linked heterodimer, Iga/Igb (CD79a/CD79b) co-
receptor (Hombach et al., 1990; Radaev et al., 2010). In the cytoplasmic domain of each CD79 
molecule, there is an immunoreceptor tyrosine-based activation motif (ITAM), which upon 
BCR stimulation gets phosphorylated by a SRC-family kinase, predominantly LYN (Rolli et 
al., 2002; Tolar et al., 2008). This leads to the activation of phosphatidylinositol-3-kinase 
(PI3K) and spleen tyrosine kinase (SYK). PI3K generates phosphatidylinositol-3,4,5-
trisphosphate (PIP3) that allows translocation of BTK onto the cell plasma membrane (Salim 
et al., 1996). Activated LYN phosphorylates BTK on the Y551 residue, leading to activation 
of BTK. This is followed by autophosphorylation of the Y223 residue in the SH3 domain 
(Figure 2a).  
Phospholipase C-g2 (PLCg2) is activated by BTK and a signalosome composed by SYK, BTK, 
PLCg2 and the protein adaptor BLNK/SLP-65 is then produced. Phosphatidylinositol-3,4,5-
triphosphate is cleaved by PLCg2 into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3) (Herrera and Jacobsen, 2014). This increases the levels of intracellular calcium resulting 
in the activation of protein kinase Cb (PKCb) and transcription factors involved in the 
regulation of B-cell proliferation, differentiation, survival and migration (Figure 2a) (Herrera 
and Jacobsen, 2014). 
 
Figure 2. Schematic representation of BTK and BTK-inhibitors role in the BCR signaling pathway. (A) BCR-
BTK signaling pathway. (B) Inhibition of the BTK´s catalytic activity caused by covalent BTK inhibitors. BTK 
protein is depicted with all five domains (SH1-3, TH and PH), two phosphorylation sites Y551/Y223 and the 
corresponding cysteine-481 inhibitor binding site. C-BTKi indicates covalent BTK inhibitor; C, cysteine; Y, 








































1.5 BTK outside the B-cell receptor signaling pathway 
The role of BTK in other cell compartments, aside from B-lymphocytes, has emerged from the 
study of XLA patients and the BTK-deficient mouse model (Schmidt et al., 2004). In 
macrophages, BTK gets activated upon lipopolysaccharide (LPS) stimulation leading to the 
tumor necrosis factor alfa (TNFa) production (Horwood et al., 2003). Monocytes and 
macrophages lacking BTK show impaired chemotaxis/phagocytic function (Braga Amoras et 
al., 2003) and reduced secretion of the proinflammatory cytokines TNFa and interleukin-1ß 
(IL-1ß), respectively (Mukhopadhyay et al., 2002).  
Mast cells have a key role in the initiation of allergic reactions, they are primarily activated by 
cross-linking of the high-affinity IgE receptor, which leads to cell degranulation, histamine and 
cytokine secretion (Schmidt et al., 2004). BTK-deficient mast cells have impaired secretion of 
proinflammatory cytokines such as IL-2 and TNFa (Hata et al., 1998), show spontaneous 
degranulation in the absence of stimulation and increased proliferation potential (Dvorak et al., 
1996; Kawakami et al., 2000).  
BTK-deficient megakaryocytes, in mice, display a reduced intracellular Ca2+ mobilization 
(Pasquet et al., 2000) and platelets from XLA carriers have reduced aggregation response upon 
collagen induction (Quek et al., 1998; Berglöf et al., 2015). However, XLA patients do not 
suffer from bleeding and present normal megakaryocyte development, suggesting an 
alternative compensatory mechanism (Berglöf et al., 2015). In addition, an important role of 
BTK has also been described in the survival of neutrophils and activation of NK-cells and 
dendritic cells (Bao et al., 2012; Honda et al., 2012; Lougaris et al., 2014). 
 
1.6 BTK inhibition in B-cell malignancy  
The central role of BTK in tumorigenesis is still debated and not well understood. Gain-of-
function substitutions in BTK were not reported in patients with B-cell malignancies (Smith, 
2017b). However, it was described that overexpression and constitutive BTK phosphorylation 
lead to activation of PLCg2 and downstream molecules, which promote upregulation of pro-
survival signals and migration in chronic lymphocytic leukemia (CLL) cells (Herman et al., 
2011). In mantle cell lymphoma (MCL) cells BTK was shown to be important for adhesion 
and chemotaxis (Chang et al., 2013).     
In animal models, it was demonstrated that blocking of the BCR signaling pathway may cause 
lymphomas, by combining and inactivating mutations in both BTK and BLNK (Kersseboom 
et al., 2003). However, this scenario is very unexpected in patients due to the requirement of 
multiple mutations in the DNA (Smith, 2017b). While patients with XLA only show clinically 
relevant defects in B-cells, other BTK-containing cells in the microenvironment may still 
promote tumor growth and hence inhibition of BTK could play a role apart from an effect on 
the tumor B-cell per se. For instance, BTK inhibition by ibrutinib was demonstrated in myeloid 
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derived suppressor cells, which are known as critical contributors of tumor evasion and 
promoters of immune suppression (Stiff et al., 2016). 
On the other hand, it is known that BTK has an essential role in the proliferation, migration 
and survival of malignant B-cells (De Rooij et al., 2012, 2015). Therefore, BTK inhibitors 
(BTKis) were developed and have revolutionized the treatment of B-cell malignancies (Pal 
Singh et al., 2018; Lucas and Woyach, 2019).  
 
1.6.1 Irreversible BTK inhibitors 
Ibrutinib (PCI-32765, Imbruvica®) is the most studied BTKi (Honigberg et al., 2010; Herman 
et al., 2011; Byrd et al., 2013; Burger et al., 2015; Smith, 2017b) and first-in-class irreversible 
binder that has been approved by the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA). Ibrutinib is indicated for the treatment of adults with at 
least one prior therapy in MCL, previously treated or untreated CLL/small lymphocytic 
leukemia (SLL) and Waldenström macroglobulinemia (WM). FDA also indicates ibrutinib for 
previously treated marginal zone lymphoma (MZL) patients and chronic graft-versus-host 
disease (cGVHD) (FDA., 2020).  
Ibrutinib blocks the catalytic activity of BTK by forming a covalent bond between its 
acrylamide moiety and the thiol group of the cysteine (C) 481 located in the ATP-binding site 
of the BTK (Figure 2b and 3) (Johnson et al., 2016; Chen et al., 2018; Gehringer and Laufer, 
2019). Two additional hydrogen bonds were described with the Glu475 and Met477 residues 
in the BTK kinase domain (Figure 3) (Johnson et al., 2016). Ibrutinib is a small-molecule BTK 
inhibitor that reaches maximum serum concentration of ~0.5 µM, one to two hours after oral 
administration (420 mg, once-daily dose). It is rapidly absorbed and has a half-life of 4 to 6h  
(Advani et al., 2013; Marostica et al., 2015). Inhibition of BTK by ibrutinib showed, overall 
response rate (ORR) of 83 to 97% in relapsed/refractory (R/R) CLL patients, (O’Brien et al., 
2016; Ahn et al., 2018) 90 to 92% in rituximab-refractory WM patients (Dimopoulos et al., 
2017; Treon et al., 2018; Castillo and Treon, 2020) and 68 to 70% in R/R MCL patients (Wang 





Figure 3. Molecular model of ibrutinib covalently bound to BTK. Right panel shows ibrutinib chemical structure, 
blue and orange ovals indicate sites of formation of hydrogen and covalent bond, respectively. Adapted with 
permission from Johnson, A. et al. (2016). Battling Btk Mutants with Noncovalent Inhibitors That Overcome 
Cys481 and Thr474 Mutations. ACS Chem. Biol. 11, 2897–2907. Copyright 2016 American Chemical Society. 
 
Due to the therapeutic success of ibrutinib but also due to the fact that this drug causes side 
effects, a second generation of more selective BTKis was developed. Acalabrutinib (ACP-196, 
Calquence®), zanubrutinib (BGB-3111, Brukinsa®) and tirabrutinib (Velexbru®) are 
examples and new FDA-approved BTKis.  
Acalabrutinib also covalently binds to the C481 residue in the BTK kinase domain, and has 
been reported to show higher selectivity and reduced number of off-targets compared with 
ibrutinib (Table 1) (Byrd et al., 2016). Acalabrutinib is FDA- and EMA-approved for the 
treatment CLL/SLL patients and only FDA approved for MCL (Markham and Dhillon, 2018; 
FDA., 2019b). Its efficacy has been evaluated in CLL and other B-cell malignancies and a high 
ORR has been shown in patients with R/R disease (Markham and Dhillon, 2018; Wang et al., 
2018; Byrd et al., 2020b). Zanubrutinib is also a next generation BTK inhibitor suggested to be 
more selective than ibrutinib (Table 1) (Guo et al., 2019). It has shown potent clinical activity 
and high ORR with minimal off-target effects in phase 1/2 studies, when used for the treatment 
of MCL and CLL/SLL patients (Seymour et al., 2017; Tam et al., 2018). Zanubrutinib was 
FDA approved for MCL, EMA approved in pretreated WM patients, and in China the National 
Medical Products Administration (NMPA) approved zanubrutinib for CLL/SLL and pretreated 
MCL patients (FDA., 2019a). Tirabrutinib got approval by the Pharmaceuticals and Medical 
Devices Agency (PMDA) in Japan for treatment of R/R primary central nervous system 
lymphoma and WM (Dhillon, 2020). This is a highly expanding field and only for the last three 





Table 1. Selectivity and adverse events in approved BTKis. Only kinases having a cysteine in the ATP-binding 

















BTK, BLK, BMX/ETK, EGFR, 
ERBB2/HER2, ERBB4/HER4, 
ITK, JAK3, RLK/TXK, TEC 
(Byrd et al., 2016; Guo et al., 
2019; Liclican et al., 2020) 
AF: 2 – 17% (2 – 9%)  
Rash: 2 – 47% (2 – 3%) 
Diarrhoea: 3 – 65% (2 – 16%) 
(Farooqui et al., 2015; Munir et al., 








BTK, BMX/ETK, ERBB4/HER4 
(Byrd et al., 2016; Liclican et al., 
2020) 
AF: 4 – 7% (£3%)  
Rash: 6 – 25% (0.6 – 2%) 
Diarrhoea: 17 – 58% (0.6 – 5%) 









BTK, BLK, BMX/ETK, EGFR, 
ERBB4/HER4, ITK, RLK/TXK 
(Guo et al., 2019) 
AF: £5% (<2%)  
Rash: 11 – 33% (NR) 
Diarrhoea: 8.3 – 30% (£3%) 





3 (9) BTK, BMX/ETK, TEC (Liclican et al., 2020) 
AF: 0 / NR (0 / NR)  
Rash: 19 – 44% (0 – 6%) 
Diarrhoea: 7.4 – 44% (0 – 7%) 
(Rule et al., 2020; Sekiguchi et al., 
2020) 
 
1.6.2 Adverse events and resistance to irreversible BTK inhibitors 
Ibrutinib was described as a safe BTK inhibitor, well tolerated and with rapid and durable 
response (Byrd et al., 2013, 2015; Winqvist et al., 2019). Ibrutinib has high selectivity for BTK, 
however, off-target inhibition has been reported in other kinases, which have a cysteine residue 
located in the ATP-binding site (Table 2), reviewed by (Berglöf et al., 2015). Despite the good 
results of ibrutinib in the treatment of the B-cell malignancies, adverse events and the 
emergence of resistance remain critical concerns. The most commonly observed adverse events 
that lead to ibrutinib discontinuation are atrial fibrillation (AF), bleeding, infections diarrhoea 






Table 2. Alignment of kinases that have a cysteine residue in the ATP-binding site, kinase cell expression 
and its possible association with the occurrence of the adverse event. Underlined, kinases that belong to the 
TEC family kinases; AF, atrial fibrillation. Inspired and adapted from Berglöf, A., et al. (2015). Targets for 
Ibrutinib Beyond B Cell Malignancies. Scand. J. Immunol. 82, 208–217. doi:10.1111/sji.12333.    
Protein 
Cysteine in the ATP-binding 
site, corresponding to the 
C481 in BTK 
Cell expression and possible association 
with the occurrence of BTKi adverse events 
BTK T E Y M A N G C L L N Infection: B-cells, macrophages and neutrophils 
Bleeding: platelets  
ITK F E F M E H G C L S D Infection: T-cells 
TEC  T E F M E R G C L L N 
Infection: B-, T-cells, macrophages and neutrophils        
Bleeding: platelets  
AF: cardiomyocytes 
BMX T E Y I S N G C L L N Unclear 
RLK/TXK T E F M E N G C L L N Infection: T-cells 
BLK T E Y M A R G C L L D Unclear 
JAK3 M E Y L P S G C L R D Unclear 
EGFR T Q L M P F G C L L D Rash and diarrhoea: epithelial cells 
ERBB2/HER2 T Q L M P Y G C L L D AF: cardiomyocytes 
ERBB4/HER4 T Q L M P H G C L L E AF: cardiomyocytes 
 
Higher risk of developing cardiovascular disease has been associated with ibrutinib treatment; 
the 5 years follow-up RESONATE-2 study reported AF of any grade in 16% of the treated 
patient, of which 5% developed AF ³grade 3 (Table 1) (Burger et al., 2020). Results from a 
real-world analysis including 616 CLL-patients confirmed this association and reported AF in 
12% front-line and 25% R/R treated patients (Mato et al., 2018). Development of hypertension 
or worsened high blood pressure has also been observed in more than 3/4 of ibrutinib treated 
patients (Dickerson et al., 2019). These cardiovascular events have been attributed to possible 
blocking of cardiac PI3K-Akt signaling pathway through off-target inhibition of TEC, 
ERBB2/HER2 or ERBB4/HER4 (Table 2) (Albini et al., 2011; Milano et al., 2014; Berglöf et 
al., 2015). Interestingly, results from the head-to-head ASPEN-study comparing the more 
selective BTKi zanubrutinib versus ibrutinib in WM patients, reported ≥10% higher incidence 
of AF and increased hypertension in ibrutinib treated patients, compared with zanubrutinib 
(Tam et al., 2020). Other phase III studies, comparing zanubrutinib versus ibrutinib in R/R 
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CLL/SLL (ALPINE) (Hillmen et al., 2020) and acalabrutinib versus ibrutinib monotherapy 
(NCT02477696), are ongoing and will provide further comparison.  
Increased risk for bleedings is another ibrutinib associated adverse event (Lipsky et al., 2015; 
Wang et al., 2015). An integrated analysis of 15 ibrutinib clinical studies, reported an overall 
incidence of 40% bleeding of any grade, 4% of the patients developed major haemorrhage and 
in 1% of the patients this led to treatment discontinuation (Brown et al., 2019). Low aggregation 
response and reduced adhesion have been observed in platelets from ibrutinib treated patients 
that experienced bleedings (Levade et al., 2014; Kamel et al., 2015), which correlates with the 
absence of response and highly reduced aggregation upon collagen stimulation in platelets from 
BTK/TEC dKO mice (Atkinson et al., 2003; Levade et al., 2014; Berglöf et al., 2015; Kamel 
et al., 2015). These findings suggest that inhibition of both BTK and TEC is involved in the 
increased risk of bleeding (Table 2). However, inhibition of these kinases cannot be pointed 
out as the only cause of this adverse event, since bleedings are also found upon treatment with 
BTKis that are less prone to inhibit TEC, such as acalabrutinib and zanubrutinib.     
The risk of infections also increases in ibrutinib treated patients and the risk is specially high 
during the first 6 months of treatment (Varughese et al., 2018). The results of a systematic 
review covering 48 clinical trials, showed that infections occur in 56% of patients receiving 
single-ibrutinib treatment and that >25% of the treated patients progressed to grade 3-4 
(Tillman et al., 2018). Invasive fungal infections, specially caused by Aspergillus species, are 
the most frequently identified opportunistic infections (Ghez et al., 2018; Tillman et al., 2018; 
Rogers et al., 2019). The mechanism underlying this adverse event could be associated with 
both on- and off-target kinase inhibition (Table 2). Neutropenia and reduction in the 
macrophage response are both common side effects found in treated patients (Rogers et al., 
2017; Ghez et al., 2018). Macrophages express three TEC family members BTK, TEC and 
BMX, and BTK-deficient macrophages have impaired phagocytic function, chemotaxis and 
reduced secretion of TNFα (Weil et al., 1997; Schmidt et al., 2004).  
Rash and diarrhoea are also common adverse events occurring in patients treated with 
irreversible BTKis (Table 1). The analysis of dermatological toxicity carried out (Sibaud et al., 
2020) reported a higher frequency of rash in ibrutinib treated patients (13-27%), compared with 
acalabrutinib 15-18% and zanubrutinib 13-18%. Similar to the observed for rash, the frequency 
of diarrhoea is higher in ibrutinib 3-65% (£16% ≥grade 3) than acalabrutinib 17-58% (£5% 
≥grade 3) (Table 1), and reduced number of cases were reported for zanubrutinib (21% versus 
32%) in the head-to-head ASPEN-study (Tam et al., 2020).  
Furthermore, some of the ibrutinib treated patients develop resistance. The most common cause 
of ibrutinib resistance is the cysteine-481 to serine substitution (C481S), which prevents the 
covalent binding and reduces the efficacy of the irreversible BTKis (Furman et al., 2014; 
Woyach et al., 2017; Estupiñán et al., 2020). In a cohort of 61 ibrutinib treated CLL patients, 
clonal shift was reported in 31% of the patients, after 1 year of treatment initiation (Landau et 
al., 2017), and ~60% (published data: 57 – 64.4%) of ibrutinib treated patients with disease 
progression present resistance variations, mainly in BTK (Woyach et al., 2017; Quinquenel et 
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al., 2019). Other less frequent variants, different than C481S, were reported in CLL patients 
including C481A, C481F, C481G and C481R (Furman et al., 2014; Landau et al., 2017; 
Woyach et al., 2017; Quinquenel et al., 2019).  
Substitutions in PLCg2 and the gatekeeper residue of BTK, are also involved in the 
development of resistance to BTKis. Gain-of-function substitutions in PLCg2, like S707Y and 
R665W, generate a constitutively active form, which does not need to be activated by BTK 
(Zhou et al., 2012; Woyach et al., 2014). T474I and T474S substitutions in the BTK gatekeeper 
residue have also been reported in CLL ibrutinib resistant patients, which already carry a 
previous C481S mutation. The gatekeeper residue in BTK is located in the regulatory spine of 
the kinase domain and maintains a rigid and linear structure, crucial for the catalytic activity of 
BTK (Chopra et al., 2016).  
The involvement of the gatekeeper residue in the resistance to both irreversible and the more 
recently developed reversible (non-covalent) BTKis was described (Wang et al., 2019). 
Computational structure modeling demonstrated that T474M substitution affects the binding 
of both irreversible and reversible BTKis. The reversible inhibitor RN486 was used in the 
analysis and it was shown that it binds to wild-type BTK using a hydrogen-bond network 
between K430, T474 and G414. It was also demonstrated that introducing methionine in the 
gatekeeper residue 474 of the BTK disrupted the hydrogen-bond network (Wang et al., 2019).       
Inhibitors of other kinases different than BTK are also affected by substitutions in the 
gatekeeper residue. In BCR-ABL positive chronic myeloid leukemia (CML) patients, T315I 
substitution causes resistance to imatinib (Shah et al., 2002). Crizotinib, an anaplastic 
lymphoma kinase (ALK)-inhibitor is affected by the gatekeeper variant L1196M (Kay and 
Dehghanian, 2017). Resistance to the epidermal growth factor receptor (EGFR)-inhibitors, 
gefitinib, erlotinib and afatinib, is caused by the T790M substitution in lung cancer cells (Jia et 
al., 2016).     
1.6.3 Reversible BTK inhibitors  
The reversible BTKis also known as non-covalent BTKis, are a new generation of selective 
inhibitors that are not affected by the cysteine to serine substitution. Molecular modeling 
analysis of the reversible BTKis RN486, fenebrutinib and CGI-1761 shows a unique binding 
mode in the H3 pocket of the BTK kinase domain, which is independent of the C481 and 
confers a highly selective inhibition of BTK that overcomes the resistance caused by the C481S 
substitution (Figure 4) (Estupiñán et al., 2020, 2021).  
Fenebrutinib (GDC-0853) is a highly selective BTK inhibitor, previously evaluated in healthy 
donors, resistant B-cell lymphoma and CLL patients (Byrd et al., 2018; Herman et al., 2018). 
Equivalent blocking of Y223 phosphorylation was observed when fenebrutinib was used in 
WT- and C481S-BTK transfected HEK 293T cells. Reduction of CCL3 production and cell 
death were also observed in C481S patient-clones treated with fenebrutinib (Reiff et al., 2018). 
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Fenebrutinib is currently under evaluation in phase 1 and 2 clinical trials (Chan et al., 2020), 
and more than 10 clinical trials have been reported in the NIH clinical trials database.  
Other reversible BTKis have been developed and showed potential in pre-clinical studies (Lou 
et al., 2015; Cohen et al., 2020; Estupiñán et al., 2021). For example, CGI-1746 was evaluated 
in rheumatoid arthritis and multiple myeloma mouse models and it was shown that it reduces 
cell proliferation and tumor growth (Di Paolo et al., 2011; Gu et al., 2017). RN486 was shown 
to prevent type I and type III hypersensitivity responses and inhibit both joint and systemic 
inflammation in rheumatoid arthritis mouse models (Xu et al., 2012; Lou et al., 2015).    
 
 
Figure 4. Computational docking model of BTK with reversible and irreversible BTK inhibitors. Left-center, 
kinase domain with ibrutinib (pink) in the catalytic site; N-terminal lobe (light gray); C-terminal lobe (dark gray). 
Top row shows binding of irreversible inhibitors and the bottom row of reversible inhibitors. Original residues 
T474 and C481 are in blue; substitutions at 474 methionine (yellow) and isoleucine (green), at 481 serine (yellow) 
and threonine (green). Adapted from Estupiñán, H. Y., et al. (2021). BTK gatekeeper residue variation combined 
with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and 





2 RESEARCH AIMS  
 
The overall aim of this thesis was to perform in vitro and in vivo studies of mutated BTK and 
the response to both reversible and irreversible BTKis.  
 
Specific aims: 
2.1 Paper I 
Phenotypic analysis of the mouse model with C481 to serine substitution in the BTK and 
assessment of the effects of BTKis on B- and T-lymphocytes.     
 
2.2 Paper II 
Evaluation of in vitro susceptibility of gatekeeper and combined gatekeeper/C481 BTK 





3 MATERIALS AND METHODS 
 
This chapter briefly describes some of the relevant methodologies chosen for the projects 
discussed in this thesis. Full description of the materials and methods can be found in the 
respective publications.   
 
3.1 Ethics 
Studies were approved by the local ethics committee and performed in accordance with the 
ethical permissions ID1679 and Dnr: S49-13.  
 
3.2 Cell sources     
In paper I, all the experiments were performed using primary cells obtained from the C481S 
mouse model. In paper II, expression and catalytic activity of BTK were evaluated in 
lymphoid and non-lymphoid cell lines.  
The BTK knock-out lymphoid B7.10 cell line was chosen as a relevant biological model for 
our study. It was generated from the DT40 chicken B lymphoma cell line and generously 
provided by Dr. T. Kurosaki (Nawaz et al., 2008). The non-lymphoid cell lines COS-7 (African 
green monkey fibroblast-like kidney cells) and HEK-293T (human embryonic kidney cells) 
were purchased from the American Type Culture Collection. These cell lines were selected 
because they allowed analysis without the influence of endogenous BTK.   
 
3.3 Plasmids and transient transfections 
Plasmids were generated with single and double BTK variants and transient transfections were 
performed only in paper II.  
In the non-lymphoid cell lines COS-7 and HEK-293T plasmids were transfected by using 
Polyethylenimine (PEI) (Polyscience, Inc., Warrington, PA, USA). Whereas, in the B7.10 cell 
line we carried out electroporation by using the Neon transfection system (Life Technologies, 
Carlsbad, CA, USA). A single pulse was performed with 2000 V for 20 milliseconds.    
 
3.4 Western blot 
In paper I and II, we investigated BTK protein expression, catalytic activity and its inhibition 
by western blot. First, we measured the expression of total proteins and compared it with wild-
type. Then, we analyzed the corresponding phosphorylated sites in BTK and PLCg2. 
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Phosphorylation of Y551-BTK residue indicates BTK-activation, whereas phosphorylation of 
Y223-BTK and Y753-PLCg2 reflects catalytic activity of BTK.    
Primary cells or transfected cell lines were collected after serum-free medium starvation and 
then stimulated for 5 min at room temperature. Two stimulation procedures were carried out.  
Primary B-cells and B7.10 cells were stimulated by using 4 mM H2O2 with either 10 µg/mL 
anti-mouse IgM (1022-01) or mouse anti-chicken IgM (M-4) respectively. COS-7 and HEK-
293T cells were both stimulated with FBS (2%) and pervanadate [0.02% H2O2, 1.6% Tyrode’s 
salt solution (Sigma-Aldrich) and 0.22 mM Na3VO4 (Sigma-Aldrich)]. When required, BTK 
inhibition and washout experiments were performed prior to activation. 
Whole-cell lysates were obtained by using modified RIPA buffer containing phosphatase 
inhibitor and heated at 65°C for 5 minutes with sample buffer. Samples were run at 120V for 
2h in Bis-Tris (4-12%) protein gels and MES SDS running buffer. Proteins were transferred to 
the nitrocellulose membrane by using iBlot system and membranes were blocked and incubated 
with primary and secondary antibodies as previously described (Hamasy et al., 2017). 
Membranes were scanned with the Odyssey infrared imaging system according to the 
manufacturer´s protocol.  
 
3.5 BTK inhibitors 
In both paper I and II, all BTKis used for in vitro inhibition of the BTK catalytic activity were 
dissolved in dimethyl sulfoxide (DMSO) and prior to each experiment a fresh dilution was 
prepared in serum-free medium or phosphate buffered saline (PBS).  
In paper I, for in vivo treatment, ibrutinib solution in drinking water containing 3% (2-
Hydroxypropyl)-b-cyclodextrin (H107; Sigma-Aldrich) was prepared reaching a final 
concentration of ca 0.3 mg/ml. 
 
3.6 Animal studies 
In paper I, we published the generation of a mouse model with a cysteine 481 to serine 
substitution in the exon 15 of the BTK gene, by using CRISPR/Cas9-mediated gene editing. 
The mouse model was obtained from Taconic Biosciences and the targeting strategy was based 
on National Center for Biotechnology Information (NCBI) transcript NM_013482.2. Most of 
the experiments were performed in 9-12 weeks old mice, including age- and sex- matched wild-




3.6.1 Flow cytometry  
Flow cytometry is a technique that allows multi-parametric analysis of fluorescence-labeled 
single-cell suspensions. Cell populations can be defined base on their fluorescent 
characteristics and sorted for further analysis such us cell-viability or protein expression. 
Fluorescent reagents most commonly used in flow cytometry are fluorochrome-conjugated 
antibodies, fluorescent expression proteins, DNA binding and viability dyes. 
In paper I, for the phenotypic analysis of the C481S mouse model we performed a battery of 
flow cytometry-based experiments that allowed us to determinate cellularity, cell distribution 
and expression of activation markers in selected hematopoietic cell compartments. We focused 
our analysis on the B-cell compartment, mainly in the B-cell development and distribution of 
peripheral B-cell subsets. However, hematopoietic progenitors and other non-B-lineage 
leukocytes were also analyzed.    
Cells were obtained from dissected and crushed organs, Fc-blocked by using anti-CD16/31 and 
stained with fluorochrome-conjugated antibodies as previously described (Bouderlique et al., 
2019). In order to efficiently separate positive from negatives populations, fluorescence minus 
one (FMO) controls were included in all experiments. We used propidium iodide to 
discriminate dead cells and data were acquired and analyzed on FACSAria IIu (BD 
Biosciences) and Flowjo 9.9.6 respectively. 
 
3.6.2 Cell stimulation, inhibition and cell-viability assay  
In paper I, cell-viability and CD25/CD69 expression were evaluated upon B- and T-cell 
stimulation with/without BTK inhibitors.  
For B- and T-lymphocyte activation, 2´106 splenocytes were seeded in a 24-well plate, 
containing either IMDM medium with 15% FCS and 50 mM b-mercaptoethanol for B-
lymphocytes or RPMI 1640 medium with 10% FCS for T-lymphocytes. B-lymphocytes were 
stimulated by adding 20 µg/mL of anti-mouse IgM (1022-01) and T-lymphocytes by coating 
the 24-well plate with 10 µg/mL of anti-CD3e (145- 2C11).  
BTK inhibition was performed five minutes after stimulation and cells were cultured for 30 
hours at 37°C. Then, cells were harvested and stained with fluorochrome-conjugated 
antibodies. CD25/CD69 expression and cell-viability were evaluated by using flow-cytometry 
based protocols. LIVE/DEAD Aqua (Invitrogen) was used for dead cell discrimination, data 
were acquired and analyzed on FACSAria IIu (BD Biosciences) and Flowjo 9.9.6 respectively. 
 
3.6.3 Enzyme-linked immunosorbent assay (ELISA) 
Reduced IgM and almost total lack of IgG3 antibody levels are found in BTK-deficient mice 
(Scher, 1982; Khan et al., 1995; Ellmeier et al., 2000). In paper I, to investigate if this anomaly 
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was present in our C481S mouse model, we performed ELISA for total IgM, IgG and IgG3 
antibodies. Also, we have studied the production of anti-DNA antibodies as an indication of 
autoimmune response, which has been frequently seen in aged mice with dysregulated 
immunoglobulin production (Scher, 1982; Bygrave et al., 2004; Nusser et al., 2014).    
For total immunoglobulin quantification, serum dilutions were prepared and incubated on anti-
IgG (H+L) coated plates. Then, horseradish peroxidase (HRP)–conjugated goat anti-mouse 
IgG, IgM, and IgG3 antibody was added to the plate and incubated for 1 hour at 37°C. 
Developing, blocking and reading were performed by using 3,3’,5,5´-tetramethylbenzidine 
(TMB) substrate set, sulfuric acid (1 M) and Bio-Rad microplate reader (450 nm) respectively. 
For anti-DNA reaction, serum was incubated on plates coated with methylated bovine serum 
albumin and calf thymus DNA. Then, anti-mouse immunoglobulin-HRP was added on the 
plates and treated as described previously. 
 
3.6.4 Immunohistochemistry 
In paper I, to evaluate that our C481S mouse model did not have altered structure of B-cell 
compartments in peripheral lymphoid organs, we compared C481S with wild-type mice by 
performing immunohistochemistry in spleen and lymph nodes.   
Spleens and lymph nodes were frozen and sectioned by using cryostat microtome. Then, 8-
mm-thick slides were prepared, dried and fixed in acetone. Slides were serum-blocked and 
stained with biotin- or fluorophore-conjugated antibodies. Afterward, sections were washed 
and incubated with fluorophore-conjugated streptavidin. Slides were prepared with ProLong 
Diamond Antifade Mountant (Thermo Fisher Scientific), data were acquired with a confocal 





4 RESULTS AND DISCUSSIONS 
 
4.1 Paper I 
Ibrutinib BTK-inhibition has revolutionized the treatment strategy for B-cell malignancies 
(Honigberg et al., 2010; Advani et al., 2013; Lucas and Woyach, 2019) and demonstrated a 
remarkable therapeutic effect even during long-term follow-up (Byrd et al., 2019). However, 
the emergence of resistance (Woyach et al., 2017; Quinquenel et al., 2019) and the ibrutinib 
off-target binding adverse events are of concern (Jain et al., 2017; Mato et al., 2018; Munir et 
al., 2019). In this study, we generated a mouse model carrying the C481 to serine substitution 
(C481S), which is the most common ibrutinib resistant variant abrogating the covalent binding 
of ibrutinib to the thiol group located at the ATP-binding site (Furman et al., 2014; Woyach et 
al., 2017).    
Lack of functional BTK in mice causes partial arrest of the B-cell development leading to an 
increase of proB-cells and decrease of immature and mature B-cells (Khan et al., 1995; 
Ellmeier et al., 2000). Peripheral B-cell populations are affected in these mice. Reduction of 
both IgM+ and mature IgMlo/IgDhi B-cells is observed in spleen and lack of CD5+ B1a cells in 
peritoneal cavity (Scher, 1982; Khan et al., 1995; Ellmeier et al., 2000). To investigate if the 
C481S substitution has impact on the B-cell development, we used flow cytometry-based 
protocols for the identification of B-cell progenitors in BM and peripheral B-cell subsets in 
spleen, blood and peritoneal cavity. We found similar distribution and cellularity of the 
analyzed B-cell subsets, with no significant differences between C481S and wild-type mice.  
We conducted immunohistochemical analysis of spleens and lymph nodes to determine if the 
B-cell spatial distribution or the structure of peripheral lymphoid organs remained also 
unaffected in the C481S model. In spleen, we found maintained follicular structure with well-
defined B- and T-lymphocyte areas and unaffected metallophilic macrophage distribution and 
localization. Lymph nodes from C481S mice were similar to wild-type, with defined central T-
cell areas and round B-cell follicles. We further analyzed serum antibody levels and found no 
significant differences in total IgM, IgG and IgG3. In contrast to the observations in our C481S 
mouse model, Xid and the corresponding knock-out mice have discontinued MZ macrophage 
layer, reduced IgM production and very low IgG3 levels (Khan et al., 1995; Ochs and Smith, 
1996; Ellmeier et al., 2000). Other non-B-lineage leukocytes and hematopoietic progenitor 
were also analyzed and we found no significant changes in the C481S animals. Taken together, 
we demonstrated that mice carrying the C481S substitution have no detectable loss-of-function 
phenotype and hematopoiesis is overall normal. 
We further investigated if the C481S substitution could potentially lead to autoimmune disease, 
caused by dysregulation of B-cell activation in aged mice. We measured anti-DNA reactivity, 
evaluated peripheral B-cell subsets and histopathological changes in 16 and 20 months old 
mice. We did not find any manifestation of autoimmune disease in aged C481S mice. We found 
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no significant differences in anti-DNA antibodies and in line with the results obtained from 
young mice, most of the analyzed B-cell subsets from C481S remain similar to the 
corresponding wild-type subsets. No significant changes were observed when 
histopathological analysis was carried out for heart, kidney, liver and lung.  
Reversible, non-covalent BTKis are a new generation of selective molecules designed to 
overcome resistance caused by the C481S substitution (Furman et al., 2014; Johnson et al., 
2016; Woyach et al., 2017). In order to evaluate if the C481S substitution confers resistance, 
we performed in vitro and in vivo inhibition by using the reversible (RN486) and irreversible 
(ibrutinib, acalabrutinib and zanubrutinib) BTKis.  
We measured BTK´s catalytic activity by phosphorylation of Y223-BTK/Y753-PLCg2 and 
showed that in vitro BTK-inhibition by ibrutinib but not RN486 was affected by the C481S 
substitution. Ibrutinib blocked phosphorylation of both Y223-BTK and Y753-PLCg2 in B-
lymphocytes from wild-type but minimally from C481S. This finding was confirmed by in vivo 
experiments. When mice were given ibrutinib solubilized in drinking water, BTK´s catalytic 
activity was inhibited only in wild-type mice. 
BTK not only plays a crucial role in development, it is also important for the survival of B-
cells (Tsukada et al., 1993; Vetrie et al., 1993; Khan et al., 1995; Bestas et al., 2014). Apoptosis 
is induced in absence of functional BTK or upon BTK-inhibition (Reiff et al., 2018; Lucas and 
Woyach, 2019; Wang et al., 2019). We conducted viability assay and demonstrated that 
stimulated B-cells from C481S mice survived treatment with irreversible BTKis (ibrutinib, 
acalabrutinib and zanubrutinib) even at high concentrations (ibrutinib and zanubrutinib). In 
contrast, cell death was observed with RN486 regardless the inhibitory concentration.  
Expression of the CD25/CD69 B-cell activation markers upon anti-IgM stimulation and BTK-
inhibition was also assessed in wild-type and C481S mice. We found that irreversible BTKis 
weakly inhibit CD25/CD69 expression, whereas it was completely blocked by RN486. On the 
other hand, expression of both activation markers was drastically reduced in wild-type cells 
after stimulation regardless of which inhibitor was used. Taken together, results from BTK´s 
catalytic activity, viability assay and expression of B-cell activation markers, we concluded 
that B-lymphocytes from C481S mice are resistant to irreversible, but sensitive to reversible 
BTKis.  
The C481S mouse model, is unique in the sense that it allows us to study the off-target adverse 
events caused by irreversible BTKis, without blocking BTK expression or catalytic activity. 
This is because any treatment effect is expected to remain upon binding of the inhibitor to 
kinases other than BTK.  
The IL-2-inducible kinase (ITK) belongs to the group of 10 kinases, which have a cysteine 
residue in the ATP-binding site similar to BTK and it is crucial molecule for the T-cell receptor-
mediated activation and proliferation. We studied if ibrutinib would have a BTK-independent 
effect on anti-CD3 stimulated T-cells, by measuring the expression of CD25/CD69 activation 
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markers in wild-type and C481S mice. After anti-CD3 stimulation and ibrutinib treatment, we 
found >50% reduction of CD25/CD69 co-expression (ibrutinib concentration: 0.25 µM) and 
total lack of CD25 expression (ibrutinib concentration: 1.0 µM) in both CD4+ and CD8+ T-
cells, regardless of mouse genotype. This is in agreement with impaired T-cell function 
reported in ibrutinib-treated patients (Dubovsky et al., 2013) and demonstrates the potential of 
the C481S knock-in mouse model to study the mechanism underlying off-target associated side 




4.2 Paper II 
The gatekeeper residue is located in the regulatory spine of the tyrosine kinase domain (Joseph 
et al., 2010) and plays an important role in the resistance to several tyrosine kinase inhibitors 
(Smith, 2017a). Gatekeeper variants have been associated with impaired binding of inhibitors 
and increased ATP-binding affinity (Shah et al., 2002; Jia et al., 2016; Kay and Dehghanian, 
2017).  In BTK, gatekeeper variants have been detected in treated CLL patients in presence of 
the C481S substitution (Maddocks et al., 2015) and co-occurrence of gatekeeper and kinase 
domain variants in cis has been reported by using BTK mutagenesis screening (Wang et al., 
2019). In this study we evaluated 16, both single and double BTK variants (Table.1) and 
demonstrated how simultaneous substitutions of the gatekeeper T474 and the C481 residues 
located at the ATP-binding side, result in super-resistance to three clinically approved BTKis. 
 
Table 1. Substitutions at T474 and C481. From Estupiñán, H. Y., et al. (2021). BTK gatekeeper residue variation 
combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib 
and zanubrutinib. Leukemia, Online ahead of print. doi:10.1038/s41375-021-01123-6 
 
 
In order to evaluate BTK protein expression and catalytic activity, without influence of 
endogenous BTK, we performed transient transfection of the gatekeeper variants into the non-
lymphoid COS-7 cell line. Similar levels of protein expression were observed for all the 
gatekeeper variants. The catalytic activity, evaluated by Y223-BTK phosphorylation and 
compared to wild-type, was reduced in T474A/N/P, T474A/C481S and T474S/C481S variants. 
Double BTK variants T474I/C481S, T474M/C481S and T474M/C481T showed significantly 
elevated kinase activity. We confirmed also the expression and activity of selected BTK 
gatekeeper variants in the lymphoid and non-lymphoid cell lines B7.10 and HEK-293T. 
We further investigated if irreversible BTK binders are able to block the kinase activity of the 
gatekeeper variants, initially by performing in vitro inhibition assay with ibrutinib in 
transfected COS-7 and HEK-293T cells. Ibrutinib at 0.5 µM, which is the pharmacological 
concentration obtained in serum of treated patients (Byrd et al., 2013), blocked Y223-BTK 
phosphorylation in most of the single variants and unexpectedly also in T474A/C481S and 
partially in T474S/C481S double variants. The single T474M variant was fully sensitive only 
when 4 µM ibrutinib concentration was used, whereas double BTK variants T474I/C481S, 
T474M/C481S and T474M/C481T showed an interesting super-resistance even when ibrutinib 
was increased more than 120-fold (64 µM) over the physiological concentration. We confirmed 
the results obtained from COS-7 cells in HEK-293T cells.    
*Alanine Asparagine Isoleucine Proline Serine Threonine
(A) (N) (I) (P) (S) (T)
GCT AAT ATT CCT
Fenilalanine Glutamic acid Glutamine Leucine Methionine Valine 
(F) (E) (Q) (L) (M) (V)
TTC GAA CAG CTG ATG GTG
Two or three 
substitutions AGC ACC








Acalabrutinib and zanubrutinib were used to further study if the ibrutinib super-resistant 
variants, T474I/C481S, T474M/C481S and T474M/C481T, are also resistant to the second 
generation of irreversible BTKis. We confirmed that BTK’s catalytic activity was not 
completely blocked even at 96 µM of acalabrutinib, and similar to ibrutinib very high 
concentration of zanubrutinib (64 µM) was needed to partially inhibit the variants that are 
super-resistant to ibrutinib.      
The sensitivity of the generated substitutions was further examined by utilizing bioinformatic 
and structural analysis. We hypothesize that super-resistance emerges in the double variants 
because the binding interactions with the irreversible inhibitors are lost or modified. 
Substitutions at C481 in BTK affect the ability of the inhibitor to form a covalent bond reducing 
its binding to only non-covalent targets, which seems to be lost upon the T474M/I replacements 
at the gatekeeper residue. On the other hand, the unexpected sensitivity of the double variants 
T474S/C481S and T474A/C481S could be explained by the fact that T474S/A substitutions 
results in smaller side chains, making the binding pocket wider and accessible to the inhibitor. 
Additionally, the serine substitution could retain the polar character of the side chain and the 
hydrogen binding to the inhibitor. 
Non-covalent BTKis bind to the H3 pocket in the kinase domain by forming a network of 
hydrogen bonds in an orthogonal binding mode (Johnson et al., 2016; Crawford et al., 2018; 
Wang et al., 2019). Therefore, their binding is not affected by the C481S substitution and 
compounds such as fenebrutinib has shown in vitro inhibitory capacity against single C481S/R 
and T474I/M BTK variants (Byrd et al., 2018). To evaluate the potential of reversible inhibitors 
as treatment for the BTK super-resistant variants, we obtained the commercially available 
RN486, fenebrutinib and CGI-1746 BTKis, and tested them in transfected COS-7 cells. We 
confirmed that all three compounds have inhibitory capacity and could be suitable for the 
treatment of patients that carry C481S/T substitutions. However, only RN486, at a clinically 





5 CONCLUSIONS AND FUTURE PERSPECTIVES  
 
The therapeutic landscape of B-cell malignancies has been revolutionized by the introduction 
of ibrutinib and it evolves rapidly towards the development of more selective BTKis, and 
molecules with new binding strategies that overcome resistance. The implementation of 
combined therapies, such as, BTKis with either anti-CD20 or B-cell lymphoma 2 (BCL2) 
protein inhibitors, has also been reported. Here, I describe the main contribution of this thesis 
to the research field.  
In the paper I, we generated a novel knock-in mouse model for the most common resistance 
mutation cysteine 481 to serine substitution in the catalytic domain of BTK. In the C481S 
mouse model, we demonstrated that BTK is not susceptible to the treatment with irreversible 
BTKis, such us, ibrutinib, acalabrutinib or zanubrutinib. Furthermore, by analyzing the effects 
of ibrutinib on T-cells, we showed the potential of the C481S mice for studying both adverse 
events and new therapeutic targets unrelated to inhibition of BTK.  
Our next step is to initiate treatment of the C481S mouse model with newly developed and 
more selective BTKis, such as evobrutinib. In a BTK independent manner, we could evaluate 
by RNA-seq the effects of evobrutinib and compare these with results obtained from C481S 
mice treated with ibrutinib. It would be interesting to determinate if there are differences in the 
RNA-seq data from cardiomyocytes, epithelial and blood cells, since evobrutinib does not 
inhibit ERBB2/HER2, EGFR, RLK/TXK and ITK kinases.    
Additionally, we are interested to generate a new mouse model that develops tumors resistant 
to BTKis. We have acquired Eµ-TCL1 mice that develop spontaneous CLL and do not have 
any BTK alteration. We will generate a C481S-BTK/Eµ-TCL1 strain, that we speculate would 
mimic the same neoplastic resistance found in humans. Studies of irreversible BTKis in this 
new model would provide information about e.g. the effects of the BTKis in a tumor 
microenvironment not sensitive to BTK inhibition.     
In paper II, we showed another potential resistance mechanism, caused by threonine 474 to 
methionine substitution in the BTK gatekeeper residue, for which BTK´s catalytic activity 
inhibition requires eight times higher ibrutinib concentration. We demonstrated that 
simultaneous substitution of the gatekeeper residue T474 and of the C481 inhibitor binding site 
unexpectedly results in super-resistance to the three clinically approved BTKis acalabrutinib, 
ibrutinib and zanubrutinib. Additionally, we suggested that three non-covalent BTKis (RN486, 
fenebrutinib and CGI-1746) could be considered as treatment option for ibrutinib-resistant 
patients with single BTK mutations and RN486 for the super-resistant variants. However, this 
needs further investigation.  
As a follow up of this project we are already studying the influence of gatekeeper residue 
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